Pharming (PHAR) Cash from Investing Activities (2019 - 2026)

Pharming (PHAR) has 7 years of Cash from Investing Activities data on file, last reported at -$45000.0 in Q4 2025.

• Quarterly Cash from Investing Activities rose 99.54% year-over-year to -$45000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$134.9 million (up 30.14% YoY) and the FY2025 annual result came in at $26.3 million, down 16.97% from the prior year.
• Cash from Investing Activities improved to -$45000.0 in Q4 2025, from -$9.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $4.4 million in Q3 2024 to a low of -$129.4 million in Q4 2023.
• A 5-year average of -$27.1 million and a median of -$5.0 million in 2021 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 34403.47% — and 2024, when it soared 107.47%.
• Tracing PHAR's Cash from Investing Activities over 5 years: stood at -$2.6 million in 2021, then soared by 85.38% to -$375000.0 in 2022, then slumped by 34403.47% to -$129.4 million in 2023, then soared by 92.43% to -$9.8 million in 2024, then surged by 99.54% to -$45000.0 in 2025.
• The last three Cash from Investing Activities figures came in at -$45000.0 (Q4 2025), -$9.8 million (Q4 2024), and $4.4 million (Q3 2024), per Business Quant data.